Relay Therapeutics (RLAY) Expected to Announce Quarterly Earnings on Thursday

Relay Therapeutics (NASDAQ:RLAY) will likely be releasing its Q1 2025 earnings data before the market opens on Thursday, May 1st. Analysts expect the company to announce earnings of ($0.51) per share and revenue of $0.01 million for the quarter.

Relay Therapeutics (NASDAQ:RLAY) last announced its quarterly earnings results on Wednesday, February 26th. The company reported ($0.45) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.57) by $0.12. On average, analysts expect Relay Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Relay Therapeutics Stock Performance

Shares of Relay Therapeutics stock opened at $3.11 on Thursday. The company has a market cap of $526.37 million, a P/E ratio of -1.19 and a beta of 1.70. Relay Therapeutics has a fifty-two week low of $1.78 and a fifty-two week high of $10.72. The firm has a 50-day simple moving average of $3.05 and a two-hundred day simple moving average of $4.35.

Wall Street Analyst Weigh In

A number of analysts have recently commented on RLAY shares. Wells Fargo & Company started coverage on shares of Relay Therapeutics in a research note on Thursday, April 17th. They set an “equal weight” rating and a $4.00 target price for the company. Stifel Nicolaus decreased their target price on Relay Therapeutics from $27.00 to $23.00 and set a “buy” rating on the stock in a research report on Thursday, February 27th. HC Wainwright reiterated a “buy” rating and set a $16.00 price target on shares of Relay Therapeutics in a research report on Friday, March 7th. Finally, The Goldman Sachs Group decreased their price objective on Relay Therapeutics from $20.00 to $18.00 and set a “buy” rating on the stock in a report on Thursday, February 27th. Two analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $18.36.

Insider Activity

In other news, CFO Thomas Catinazzo sold 36,036 shares of the business’s stock in a transaction that occurred on Tuesday, January 28th. The shares were sold at an average price of $4.63, for a total value of $166,846.68. Following the sale, the chief financial officer now directly owns 263,190 shares of the company’s stock, valued at approximately $1,218,569.70. The trade was a 12.04 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Peter Rahmer sold 17,250 shares of the business’s stock in a transaction that occurred on Thursday, January 30th. The shares were sold at an average price of $4.42, for a total value of $76,245.00. Following the completion of the sale, the insider now directly owns 402,431 shares in the company, valued at approximately $1,778,745.02. The trade was a 4.11 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 296,418 shares of company stock valued at $1,175,793 in the last quarter. Insiders own 4.32% of the company’s stock.

Relay Therapeutics Company Profile

Relay Therapeutics, Inc operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology and genetic disease indications. The company’s lead product candidates include RLY-4008, an oral small molecule inhibitor of fibroblast growth factor receptor 2 (FGFR2), which is in a first-in-human clinical trial for patients with advanced or metastatic FGFR2-altered solid tumors; RLY-2608, a lead mutant-PI3Ka inhibitor program that targets phosphoinostide 3 kinase alpha; and Migoprotafib (GDC-1971), an oral, small molecule, potent and selective inhibitor of the protein tyrosine phosphatase SHP2 that binds and stabilizes Src homology region 2 domain-containing phosphatase-2 (SHP2) as a monotherapy in patients with advanced or metastatic solid tumors.